Clinical Trials | March 05, 2026
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
